Richter Welcomes Generic Xarelto And Pradaxa Impact As Revenues Climb In 2024
‘Not A Big Bang,’ Firm Admits, But Steady Addition To Operations; Biosimilars Advancing
Gedeon Richter enjoyed a solid 2024 as it capitalized on key generic launches and progressed significantly with proposed biosimilars to both Prolia/Xgeva and Actemra/RoActemra. The Hungarian firm also shed light on its strategy over the next decade in a newly-launched ten-year strategic plan.
